Champions Oncology, Inc. (CSBR)

Market Cap	64.84M
Revenue (ttm)	51.66M
Net Income (ttm)	-3.40M
Shares Out	13.59M
EPS (ttm)	-0.25
PE Ratio	n/a
Forward PE	33.72
Dividend	n/a
Ex-Dividend Date	n/a

Volume	30,061
Open	4.810
Previous Close	4.890
Day's Range	4.710 - 4.970
52-Week Range	3.600 - 7.130
Beta	0.45
Analysts	Strong Buy
Price Target	6.75 (+41.51%)
Earnings Date	Sep 11, 2024

About CSBR

Champions Oncology, Inc., a technology-enabled research company, provides transformative technology solutions for drug discovery and development in the United States. The company, through its Tumorgraft Technology Platform, provides personalized cancer care based upon the implantation of human tumors in immune-deficient mice. It also offers Translational Oncology Solutions that utilizes its technology platform to assist pharmaceutical and biotechnology companies with their drug development process. In addition, it offers Lumin Bioinformatics, a...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Mar 25, 1986
• Employees: 210
• Stock Exchange: NASDAQ
• Ticker Symbol: CSBR
• Website: https://www.championsoncology.com

Financial Performance

In 2024, Champions Oncology's revenue was $50.16 million, a decrease of -6.90% compared to the previous year's $53.87 million. Losses were -$7.28 million, 36.4% more than in 2023.

Analyst Forecast

According to 2 analysts, the average rating for CSBR stock is "Strong Buy." The 12-month stock price forecast is $6.75, which is an increase of 41.51% from the latest price.

Price Target

$6.75

(41.51% upside)

Analyst Consensus: Strong Buy